Ophthalmic drug delivery technologies or mechanisms represent one of the interesting and challenging endeavors as the anatomy, physiology and biochemistry of the eye renders highly impervious properties to the foreign substances. Ocular drug delivery technologies provide several advantages such as possibility of self medication and minimal use of needles; also it enables high penetration of low molecular weight drugs and provides specific targeting within the ocular globe. On the other hand limited permeability of cornea results in low absorption of the drugs and also it renders brisk elimination of drug through the eye due to blinking and continuous tear flow and can cause unwanted systemic side effects as major portion of the dose is drained into lacrimal ducts. These factors collectively impact the growth and acceptance of several ocular drug delivery technologies. The various approaches adopted to ensure development of effective drug delivery technologies are controlled and sustained release of drugs and improvement in bioavailability. Lacrisert, Retisert, Vitrasert, Durasite and Microneedle are some of the instances of patented technologies employed in ocular drug delivery systems.
Get the Future Market Perspective for Ocular Drug Delivery Technologies at: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2869
Eye drops, systemic means, topical means and intraocular injections represent the conventional means of ocular drug delivery mechanisms. These mechanisms have several disadvantages such as increased patient discomfort, less efficient, low absorption and other side effects. Hence, this leads to the development of alternative and effective systems for delivery of ophthalmic medications. Intense research is carried out to ensure sustained and controlled release of the active agents with negligible side effects. It is observed that several drug delivery technologies are in developmental phases. For instance, intravitreal injections constitute an effective and direct approach to deliver medications to the posterior segment. However, these are associated with severe side effects such as vitreous hemorrhage, endophthalmitis, retinal detachment and cataract.
The vast research and development activities aimed at enabling the development of such ocular drug delivery modes have led to the introduction or inception of several promising technologies such as ocular inserts, collagen shields, and biodegradable polymeric systems in the global market lately. Ocular inserts enable a substantial rise in the contact time between the ocular drug and the conjunctival tissue, ensuring sustained release of drugs suitable for systemic or topical treatment. In the near future, such advanced ocular drug release mechanisms are expected to hold a commanding position in the global ocular drug delivery technologies market.
The report examines the variety of ocular drug delivery technologies presently available in the market, along with the ones that are presently in their developmental stages. The report also examines the ocular drug delivery technologies market for key regional markets such as Asia Pacific, North America, Europe, and the Rest of the World.
A detailed overview of the competitive landscape is also included in the report, with thorough business profiles of some of the most prominent vendors in the market. An analysis of major breakthroughs in terms of product innovations and approvals, activities such as mergers and acquisitions, and changes in the regulatory framework of key regional markets is also included in the report.
Some of the key companies operating in the market are Abbott Medical Optics, Hoya Corporation, CooperVision, Inc., and Bausch & Lomb, Inc.